Faculty profile

Gabriella Gobbi

ResearcherPsychiatryMcGill University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses may be missing. Find their university profile.

Gabriella Gobbi

Researcher

Psychiatry

Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
35 publications in the last five years, latest in 2026.
Senior (last) author on 15 recent papers, a sign of leading a research group.
Principal investigator on 9 research grants (9 CIHR), most recently in 2025.
Supervised 2 trainees who won CIHR awards, most recently in 2020.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

106

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Drug Discovery Molecular Biology Electrophysiology Melatonin Gpcr Mt2 Receptor Neuropathic Pain Pain

Latest papers

Cannabidiol (CBD) modulates the serotonin-kynurenine metabolic balance in the brain of morphine-tolerant neuropathic rats.
Pharmacological reports : PR · 2026
High dose of psilocybin induces acute behavioral changes without inducing conditioned place preference in Sprague-Dawley rats.
Journal of psychopharmacology (Oxford, England) · 2026 · senior author
Global perspectives on central nervous system drug innovation: achievements, barriers, and priorities for the next decade.
The international journal of neuropsychopharmacology · 2026

All 106 publications

Latest funding

Unlocking Psilocybin's Antidepressant Mechanisms: Receptor Targets, Neuronal Circuits, and m-TOR Plasticity
CIHR · 2025 · Nominated PI
$684,675
Melatonin MT2-Selective Agonists as a Novel Treatment for Fragile X Syndrome (FXS) and Phelan-McDermid Syndrome (PMS)
CIHR · 2025 · Nominated PI
$415,000
PsyTrip: an immersive psychedelic experience simulator using neurofeedback and generative AI for mental health care
SSHRC · 2024 · Co-investigator
$125,000

All 14 grants and awards

106 publications.

Cannabidiol (CBD) modulates the serotonin-kynurenine metabolic balance in the brain of morphine-tolerant neuropathic rats.

Nasini S, Pearl-Dowler L, Lopez-Canul M, Posa L, Bertazzo A, Gobbi G, Comai S

Pharmacological reports : PR2026

DOI: 10.1007/s43440-026-00850-w PMID: 41874946

High dose of psilocybin induces acute behavioral changes without inducing conditioned place preference in Sprague-Dawley rats.

Bruno V, López-Canul M, Richardson B, Camarini R, Marcourakis T, Gobbi G

Journal of psychopharmacology (Oxford, England)2026Senior author

DOI: 10.1177/02698811251368361 PMID: 40984017

Global perspectives on central nervous system drug innovation: achievements, barriers, and priorities for the next decade.

Uchida H, Gobbi G, Zohar J, Young AH, Rujescu D, Huang MC, Sundram S, Atwoli L, Vukovic J, Ikeda K

The international journal of neuropsychopharmacology2026

DOI: 10.1093/ijnp/pyag023 PMID: 42096531

Responsible artificial intelligence integration framework for psychiatric guidelines.

Mendlovic S, Frankova I, Vermetten E, Wasserman D, Schulze TG, Falkai P, Fountoulakis KN, Adorjan K, Uchida H, Fruchter E, Gobbi G, Zohar J

The international journal of neuropsychopharmacology2026

DOI: 10.1093/ijnp/pyag010 PMID: 42028724

Neurophysiological and neuropharmacological effects of melatonin MT2 receptors activation in MK-801-induced schizophrenia-like dysfunctions.

Barzon B, Marchiotto F, Nasini S, Casile A, Peluso S, Cifani C, Pitsikas N, Gobbi G, Cambiaghi M, Comai S

Biochemical pharmacology2026

DOI: 10.1016/j.bcp.2026.117725 PMID: 41571206

Uncovering novel endocannabinoidome-gut microbiome-brain axis-based therapeutic targets in a Fragile X Syndrome mouse model.

Campanale A, Mir HD, Dumais E, Inserra A, Flamand N, Chakravarty M, Gantois I, Siddiqui N, Sonenberg N, Gobbi G, Silvestri C, Di Marzo V

Progress in neuro-psychopharmacology & biological psychiatry2026

DOI: 10.1016/j.pnpbp.2025.111575 PMID: 41386393

Correction: CCNP Innovations in Neuropsychopharmacology Award: The psychopharmacology of psychedelics: where the brain meets spirituality.

Gobbi G

Journal of psychiatry & neuroscience : JPN2026First author

DOI: 10.1139/jpn-2026-0009 PMID: 41873785

Sex-sensitive serotonergic signaling in psychedelic pharmacology.

Nasini S, Barzon B, Casile A, Richardson B, Gobbi G, Comai S

Trends in pharmacological sciences2026

DOI: 10.1016/j.tips.2026.07.006 PMID: 42575820

Differential effects of psilocybin and lisuride on serotonin and dopamine neuronal activity and behavior.

Richardson B, Inserra A, Pileggi M, Prud'Homme T, Bruno V, Wan-Yan-Chan D, Shareghi-Ghahreman I, Nasini S, Strand T, Leyton M, Sonenberg N, De Gregorio D, Sprouse J, Bambico FR, Gobbi G

Progress in neuro-psychopharmacology & biological psychiatry2025Senior author

DOI: 10.1016/j.pnpbp.2025.111522 PMID: 41077262

Neuropathic pain impairs sleep architecture, non-rapid eye movement sleep, and reticular thalamic neuronal activity.

López-Canul M, Oveisi A, He Q, Vigano ML, Farina A, Comai S, Gobbi G

The international journal of neuropsychopharmacology2025Senior author

DOI: 10.1093/ijnp/pyaf017 PMID: 40121517

Unlocking Psilocybin's Antidepressant Mechanisms: Receptor Targets, Neuronal Circuits, and m-TOR Plasticity

Nominated PICIHR2025Project Grant

Principal investigators: Gobbi, Gabriella

Keywords: Antidepressant; Behavioral Pharmacology; Electrophysiology; M-Tor; Molecular Biology; Psilocybin; Psychedelics; Rapid Antidepressant

$684,675

Melatonin MT2-Selective Agonists as a Novel Treatment for Fragile X Syndrome (FXS) and Phelan-McDermid Syndrome (PMS)

Nominated PICIHR2025Team Grant: ERDERA Joint Transnational Call

Principal investigators: Gobbi, Gabriella

Keywords: Autism Spectrum Disorder; Drug Discovery; Formulation; Fragile X Syndrome (Fxs); Intracellular Signaling; Melatonin Mt2 Receptor; Optogenetics; Phelan-Mcdermid Syndrome (Pms); Sleep; Social Behavior

$415,000

PsyTrip: an immersive psychedelic experience simulator using neurofeedback and generative AI for mental health care

Co-investigatorSSHRC2024New Frontiers in Research Fund - Exploration

Principal investigators: Xiao, Yiming

$125,000

Canada Research Chairs Tier 1

Nominated PICIHR2021Canada Research Chairs - CIHR Funded - Tier 1

Principal investigators: Gobbi, Gabriella

Keywords: Crc

$1,400,000

Modulation of The Serotonin System as a Novel Therapeutic Strategy in of Autism Spectrum Disorder

SupervisorCIHR2020CIHR Fellowship

Principal investigators: Inserra, Antonio

Keywords: Autism Spectrum Disorder; Behavioural Pharmacology; Electrophysiology; Lysergic Acid Diethylamide; Molecular Pharmacology; Prefrontal Cortex; Serotonin; Serotonin 2a Receptor Agonism; Thalamus; Translational Study

$135,000

Lysergic acid diethylamide (LSD) and social behavior. A translational study.

Nominated PICIHR2020Project Grant

Principal investigators: Gobbi, Gabriella

Keywords: Ampa; Bdnf; Behavior; Biomarkers; Electrophysiology; Hallucinogens; Healthy Volunteers; Lysergic Acid Diethylamide; Optogenetic; Serotonin

$784,126

Pharmacotherapeutic effects of cannabidiol (CBD) in autism spectrum disorder (ASD)

Co-investigatorCIHR2019Team Grant: Cannabis Research in Priority Areas - Mental Health

Principal investigators: Sonenberg, Nahum; Aguilar Valles, Argel

Keywords: Autism Spectrum Disorder; Behavior; Cannabinoids; Cell Signalling; Clinical Case Study; Mental Health; Mouse Models; Neuroscience; Pharmcokinetics

$631,667

Antidepressant effect of d-lysergic acid diethylamide (LSD) microdoses

SupervisorCIHR2018CIHR Fellowship

Principal investigators: De Gregorio, Danilo

Keywords: Ampa; Behavioural Pharmacology; Drug Discovery; Electrophysiology; Hallucinogens; Lsd; Molecular Biology; Pharmacology; Prefrontal Cortex; Serotonin

$90,000

Cocaine Addiction: Epigenetic Studies in Living and Postmortem Brain

Co-investigatorCIHR2016Project Grant

Principal investigators: Leyton, Marco

Keywords: Cocaine Addiction; Epigenetic; Hdac; Micropet; Motivation; Pet; Post-Mortem Brain; Reward

$1,235,475

Adolescent cannabis consumption and risk of depression. An evidence-based approach

Nominated PICIHR2016Knowledge Synthesis Grant

Principal investigators: Gobbi, Gabriella; Ware, Mark A

Keywords: Adolescence; Cannabis; Depression; Knowledge Synthesis; Marijuana; Meta-Analysis

$100,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Gabriella Gobbi

Research

Latest papers

Latest funding

Cannabidiol (CBD) modulates the serotonin-kynurenine metabolic balance in the brain of morphine-tolerant neuropathic rats.

High dose of psilocybin induces acute behavioral changes without inducing conditioned place preference in Sprague-Dawley rats.

Global perspectives on central nervous system drug innovation: achievements, barriers, and priorities for the next decade.

Responsible artificial intelligence integration framework for psychiatric guidelines.

Neurophysiological and neuropharmacological effects of melatonin MT2 receptors activation in MK-801-induced schizophrenia-like dysfunctions.

Uncovering novel endocannabinoidome-gut microbiome-brain axis-based therapeutic targets in a Fragile X Syndrome mouse model.

Correction: CCNP Innovations in Neuropsychopharmacology Award: The psychopharmacology of psychedelics: where the brain meets spirituality.

Sex-sensitive serotonergic signaling in psychedelic pharmacology.

Differential effects of psilocybin and lisuride on serotonin and dopamine neuronal activity and behavior.

Neuropathic pain impairs sleep architecture, non-rapid eye movement sleep, and reticular thalamic neuronal activity.

PsyTrip: an immersive psychedelic experience simulator using neurofeedback and generative AI for mental health care

Frequent collaborators

Nahum Sonenberg

Marco Leyton

Linda Booij

Linda Booij

Marco Leyton

Linda Booij

Argel Aguilar Valles

Vincenzo Di Marzo

Gustavo Turecki

Nancy Low

Nicolas Flamand

Argel Aguilar Valles

Moshe Szyf

Jean-Claude Lacaille

Clement Hamani

Michael Lifshitz

Joshua Rosenblat

David Castle

David Chatenet

Marco Solmi

Alexey Kostikov

Amanpreet Badhwar

Amanpreet Badhwar

Frank Vitaro

Giamal Luheshi